8-K: C4 Therapeutics Reprices Underwater Stock Options to Retain Key Talent

C4 Therapeutics has repriced stock options for employees, including some executives, to better align incentives and retain talent.

Summary

• C4 Therapeutics' Board of Directors approved a repricing of certain stock options on March 7, 2024.
• The repricing applies to options granted under the 2020 Stock Option and Incentive Plan with an exercise price above $22.00 per share.
• The new exercise price is $19.00 per share for senior leadership and $11.88 for other employees.
• The $19.00 price matches the company's initial public offering price.
• The $11.88 price is the 52-week high trading price as of the effective date.
• The repriced options will revert to their original price if the holder leaves the company for cause or resigns (excluding death or disability) or exercises the options before March 7, 2025.
• The original exercise price of $22.00 was more than two times the closing trading price and approximately 2.5 times the 30-day volume weighted average trading price of the company's common stock on the effective date.

Sentiment

Score: 7

Explanation: The document reflects a positive move to retain talent, but the need for repricing indicates past stock performance issues. The retention period adds a layer of complexity.

Positives

• The repricing aims to retain and motivate employees by aligning their interests with the company's success.
• The repricing avoids significant stock dilution or additional cash expenditures.
• The new exercise prices are more attractive to employees given the current stock price.
• The retention period encourages employees to remain with the company.

Negatives

• The repricing only applies to options with an exercise price above $22.00, potentially excluding some employees.
• The repriced options revert to the original price if the holder leaves or exercises them before March 7, 2025, which could be seen as a restriction.

Risks

• If the company's stock price does not improve, the repriced options may still not provide sufficient incentive.
• The retention period could be seen as a disincentive for some employees who may want to exercise their options sooner.
• There is a risk that the repricing may not be enough to retain key talent if other companies offer more attractive compensation packages.

Future Outlook

The company aims to retain and motivate employees through the repriced options, aligning their interests with the company's long-term success.

Management Comments

• The Committee designed the repricing to provide added incentive to retain and motivate the holders of the Eligible Options.
• The repricing was designed to avoid stock dilution and additional cash expenditures.

Industry Context

Stock option repricing is a common practice in the biotech industry, especially when a company's stock price has declined significantly since its IPO. This move by C4 Therapeutics is likely aimed at retaining key talent in a competitive market.

Comparison to Industry Standards

• Many biotech companies with declining stock prices have repriced options to retain employees, such as Xencor and Sangamo Therapeutics.
• The use of the IPO price as a new exercise price for senior leadership is a common practice to restore value to underwater options.
• The use of the 52-week high as a new exercise price for other employees is also a common practice to provide a more attractive option price.
• The retention period is a standard mechanism to ensure employees remain with the company.

Stakeholder Impact

• Shareholders may view the repricing positively as it aims to retain key talent and align incentives.
• Employees with underwater options will benefit from the repricing.
• The repricing is not expected to have a significant impact on customers or suppliers.

Next Steps

• The repriced options will be effective as of March 7, 2024.
• The company will monitor employee retention and stock performance.

Key Dates

Keywords

stock options, repricing, employee retention, incentive plan, executive compensation, equity grants, C4 Therapeutics